Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21896395 | 0.86 | FFAR1 (0.53) | NPSR1FFAR1FFAR4KEAP1ALDH1A1 | |
| SCHEMBL13282267 | 0.86 | ALDH1A1 (0.53) | NPSR1FFAR1FFAR4ALDH1A1 | |
| SCHEMBL13254061 | 0.84 | RXFP1 (0.44) | NPSR1FFAR1FFAR4ALDH1A1 | |
| SCHEMBL12879860 | 0.83 | HDAC3 (0.46) | NPSR1FFAR1FFAR4ALDH1A1 | |
| SCHEMBL9911354 | 0.81 | MEN1 (0.50) | FFAR1ALDH1A1NR1H4 | |
| SCHEMBL12871186 | 0.80 | FFAR1 (0.55) | NPSR1FFAR1FFAR4KEAP1NR1H4 | |
| SCHEMBL659263 | 0.80 | NR1H4 (0.59) | FFAR1FFAR4KEAP1ALDH1A1NR1H4 | |
| SCHEMBL27396740 | 0.80 | FFAR1 (0.50) | NPSR1FFAR1FFAR4ALDH1A1NR1H4 | |
| SCHEMBL6557216 | 0.80 | FFAR1 (0.50) | NPSR1FFAR1FFAR4ALDH1A1NR1H4 | |
| SCHEMBL8915282 | 0.79 | FFAR1 (0.60) | FFAR1FFAR4KEAP1ALDH1A1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321766-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160096832-A1 | KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096832-A1 | KINASE INHIBITORS | ABL1, LCK, ERBB2 | NPSR1 2450/4885FFAR1 3540/4885FFAR4 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.